Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer
Public ClinicalTrials.gov record NCT00004861. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CI-994 Capsules Plus Gemcitabine Infusion Versus Placebo Capsules Plus Gemcitabine Infusion in the Treatment of Patients With Advanced Pancreatic Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or giving drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of gemcitabine with or without CI-994 in treating patients who have advanced pancreatic cancer.
Study identification
- NCT ID
- NCT00004861
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 1999
- Primary completion
- Not listed
- Completion
- Aug 31, 2001
- Last update posted
- Aug 9, 2012
1999 – 2001
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars-Sinai Comprehensive Cancer Center | Los Angeles | California | 90048 | — |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| Sinai Hospital of Baltimore | Baltimore | Maryland | 21225 | — |
| William Beaumont Hospital | Royal Oak | Michigan | 48073 | — |
| Raleigh Hematology/Oncology Associates - Wake Practice | Raleigh | North Carolina | 27609 | — |
| Jewish Hospital of Cincinnati, Inc. | Cincinnati | Ohio | 45236 | — |
| Ireland Cancer Center | Cleveland | Ohio | 44106-5065 | — |
| West Clinic, P.C. | Memphis | Tennessee | 38117 | — |
| Sarah Cannon-Minnie Pearl Cancer Center | Nashville | Tennessee | 37203 | — |
| Tyler Cancer Center | Tyler | Texas | 75702 | — |
| Northern Virginia Oncology Group | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00004861, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 9, 2012 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00004861 live on ClinicalTrials.gov.